Preoperative chemo-CIRT in Re/BRe pancreatic cancer: Insights from a multicenter prospective phase II clinical study (NCT03822936)

Abstract

Purpose:

There is debate about the optimal management of borderline resectable (bRe) and resectable (Re) pancreatic ductal adenocarcinoma (PDAC). Both preclinical and clinical evidence showed that carbon ion radiotherapy (CIRT) produces superior control on radioresistant histologies compared to conventional photon beam radiotherapy (RT). However, so far there is a lack of data concerning the integration of CIRT in a multimodal approach with chemotherapy and surgery for bRe/Re.

Methods:

We recently presented the first analysis of a multicenter prospective phase II clinical study aimed at assessing the feasibility and effectiveness of a neoadjuvant chemotherapy + short course of CIRT followed by surgery and adjuvant chemotherapy in the management of bRe/Re PDAC. The study was terminated early due to low patient enrollment.Herein, we reported a post-hoc analysis focusing on toxicity, dosimetry and translational assessment.

Results:

In our experience, CIRT can be integrated into a multimodal treatment strategy for bRe/Re PDAC, alongside chemotherapy and surgery. A case of fatal liver failure occurring three months post-surgery has been documented, likely related to the combination approach. Although the treatment plans were satisfactory according to the Local Effect Model (LEM) model, recalculations using the modified Microdosimetric Kinetic Model (mMKM) revealed suboptimal target coverage. Additionally, we observed an increased expression of PD-L1 following CIRT.

Conclusions:

This multimodal approach was well tolerated; however, clinicians should carefully monitor for vascular disorders during follow-up and further investigate surgical techniques after CIRT. The increased PD-L1 expression supports the immunogenic effects of particle therapy and lays the groundwork for future studies. To enhance the therapeutic ratio of CIRT treatments, integrating LET-d based objectives into the plan optimization process should be considered.

Trial Registration Number:

ClinicalTrials.gov Identifier: NCT03822936

Keywords

Carbon ion radiotherapy borderline/resectable pancreatic adenocarcinomas LET PDL1

Get full access to this article

View all access options for this article.

References

Petrelli

Inno

Barni

, et al. Borderline resectable pancreatic cancer: More than an anatomical concept. Dig Liver Dis 2017; 49: 223–226.

NCCN Guidelines. Pancreatic Adenocarcinoma. Version 22023 n.d, https://www.nccn.org/guidelines/category_1 (accessed 13 November 2023).

Conroy

Pfeiffer

Vilgrain

, et al. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol 2023;34(11):987-1002.

Shinoto

Yamada

Yasuda

, et al. Phase 1 trial of preoperative, short-course carbon-ion radiotherapy for patients with resectable pancreatic cancer. Cancer 2013; 119: 45–51.

Barcellini

Vitolo

Cobianchi

, et al. Preoperative carbon ion radiotherapy (CIRT) with chemotherapy in resectable and borderline resectable pancreatic adenocarcinoma (PCa): A multicenter prospective phase II clinical study (Pioppo Study NCT 03822936). Int J Radiat Oncol Biol Phys 2023; 117: e347–348.

Vitolo

Cobianchi

Brugnatelli

, et al. Preoperative chemotherapy and carbon ions therapy for treatment of resectable and borderline resectable pancreatic adenocarcinoma: A prospective, phase II, multicentre, single-arm study. BMC Cancer 2019; 19(1): 922.

Molinelli

Vai

Russo

, et al. The role of multiple anatomical scenarios in plan optimization for carbon ion radiotherapy of pancreatic cancer. Radiother Oncol 2022; 176: 1–8.

Hagiwara

Bhattacharyya

Matsufuji

, et al. Influence of dose-averaged linear energy transfer on tumour control after carbon-ion radiation therapy for pancreatic cancer. Clin Transl Radiat Oncol 2020; 21: 19–24.

Tuveson

Neoptolemos

JP.

Understanding metastasis in pancreatic cancer: a call for new clinical approaches. Cell 2012; 148: 21–23.

10.

Gerelchuluun

Manabe

Ishikawa

, et al. The major DNA repair pathway after both proton and carbon-ion radiation is NHEJ, but the HR pathway is more relevant in carbon ions. Radiat Res 2015; 183: 345–56.

11.

Fontana

Augsburger

Grosse

, et al. Differential DNA repair pathway choice in cancer cells after proton- and photon-irradiation. Radiother Oncol 2015; 116: 374–380.

12.

Grosse

Fontana

Hug

, et al. Deficiency in homologous recombination renders Mammalian cells more sensitive to proton versus photon irradiation. Int J Radiat Oncol Biol Phys 2014; 88: 175–181.

13.

Pereira

Orlandi

Deneuve

, et al. The normal, the radiosensitive, and the ataxic in the era of precision radiotherapy: a narrative review. Cancers (Basel) 2022; 14(24): 6252.

14.

Golan

Barenboim

Lahat

, et al. Increased rate of complete pathologic response after neoadjuvant FOLFIRINOX for BRCA mutation carriers with borderline resectable pancreatic cancer. Ann Surg Oncol 2020; 27: 3963–3970.

15.

Formenti

Demaria

Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst 2013; 105: 256–265.

16.

Molinelli

Magro

Mairani

, et al. How LEM-based RBE and dose-averaged LET affected clinical outcomes of sacral chordoma patients treated with carbon ion radiotherapy. Radiother Oncol 2021; 163: 209–214.

17.

Barcellini

Peloso

Pugliese

, et al. Locally advanced pancreatic ductal adenocarcinoma: challenges and progress. Onco Targets Ther 2020; 13: 12705–12720.

18.

Okamoto

Shiba

Kobayashi

, et al. Carbon-ion radiotherapy combined with concurrent chemotherapy for locally advanced pancreatic cancer: a retrospective case series analysis. Cancers (Basel) 2023; 15(10): 2857.